Yesterday, Nov. 12, 2015, 171 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $57.69 to $70,050,500.00.

Highlighted Stocks Traded by Insiders:

Team (TISI) - FREE Research Report

Waters Louis A, who is Director at Team, sold 19,000 shares at $37.88 on Nov. 12, 2015. Following this transaction, the Director owned 160,101 shares meaning that the stake was reduced by 10.61% with the 19,000-share transaction.

The shares most recently traded at $37.75, down $0.13, or 0.35% since the insider transaction. Historical insider transactions for Team go as follows:

  • 4-Week # shares bought: 1,250
  • 4-Week # shares sold: 4,310
  • 12-Week # shares bought: 1,250
  • 12-Week # shares sold: 4,310
  • 24-Week # shares bought: 1,250
  • 24-Week # shares sold: 34,057

The average volume for Team has been 147,900 shares per day over the past 30 days. Team has a market cap of $830.7 million and is part of the services sector and diversified services industry. Shares are down 6.77% year-to-date as of the close of trading on Thursday.

Team, Inc. provides specialty industrial services in the United States, Canada, Europe, and internationally. The company operates through three segments: Inspection and Heat Treating Services (IHT); Mechanical Services (MS); and Quest Integrity. The company has a P/E ratio of 24.1. Currently, there is 1 analyst who rates Team a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on TISI - FREE

TheStreet Quant Ratings rates Team as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, a generally disappointing performance in the stock itself and poor profit margins. Get the full Team Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Orthofix International (OFIX) - FREE Research Report

Finegan Michael, who is Chief Strategy Officer at Orthofix International, sold 14,140 shares at $42.00 on Nov. 12, 2015. Following this transaction, the Chief Strategy Officer owned 58,252 shares meaning that the stake was reduced by 19.53% with the 14,140-share transaction.

The shares most recently traded at $39.92, down $2.08, or 5.21% since the insider transaction. Historical insider transactions for Orthofix International go as follows:

  • 4-Week # shares bought: 50,000
  • 4-Week # shares sold: 30,018
  • 12-Week # shares bought: 50,000
  • 12-Week # shares sold: 30,018
  • 24-Week # shares bought: 50,000
  • 24-Week # shares sold: 30,018

The average volume for Orthofix International has been 102,700 shares per day over the past 30 days. Orthofix International has a market cap of $770.7 million and is part of the health care sector and health services industry. Shares are up 31.44% year-to-date as of the close of trading on Thursday.

Orthofix International N.V., a medical device company, provides reconstructive and regenerative orthopedic and spine solutions to physicians. It operates through four segments: BioStim, Biologics, Extremity Fixation, and Spine Fixation. Currently, there are 2 analysts who rate Orthofix International a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on OFIX - FREE

TheStreet Quant Ratings rates Orthofix International as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. However, as a counter to these strengths, we find that we feel that the company's cash flow from its operations has been weak overall. Get the full Orthofix International Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Skechers USA (SKX) - FREE Research Report

Paccione Phillip, who is General Counsel & Secretary at Skechers USA, sold 8,079 shares at $28.41 on Nov. 12, 2015. Following this transaction, the General Counsel & Secretary owned 75,300 shares meaning that the stake was reduced by 9.69% with the 8,079-share transaction.

The shares most recently traded at $25.54, down $2.87, or 11.25% since the insider transaction. Historical insider transactions for Skechers USA go as follows:

  • 4-Week # shares sold: 1,000
  • 12-Week # shares sold: 1,000
  • 24-Week # shares sold: 6,413

The average volume for Skechers USA has been 4.4 million shares per day over the past 30 days. Skechers USA has a market cap of $3.4 billion and is part of the consumer goods sector and consumer non-durables industry. Shares are up 44.43% year-to-date as of the close of trading on Thursday.

Skechers U.S.A., Inc. designs, develops, markets, and distributes footwear for men, women, and children, as well as performance footwear for men and women under the Skechers GO brand name worldwide. The company has a P/E ratio of 18.2. Currently, there are 6 analysts who rate Skechers USA a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on SKX - FREE

TheStreet Quant Ratings rates Skechers USA as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Skechers USA Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.